Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

426

Participants

Timeline

Start Date

June 8, 2017

Primary Completion Date

December 1, 2021

Study Completion Date

January 3, 2022

Conditions
SchizophreniaSchizophreniform DisordersBipolar I Disorder
Interventions
DRUG

ALKS 3831

Olanzapine + samidorphan, daily oral dosing

DRUG

Olanzapine

Daily oral dosing

Trial Locations (57)

30303

Alkermes Investigational Site, Atlanta

30331

Alkermes Investigational Site, Atlanta

30912

Alkermes Investigational Site, Augusta

32209

Alkermes Investigational Site, Jacksonville

33161

Alkermes Investigational Site, North Miami

45219

Alkermes Investigational Site, Cincinnati

49001

Alkermes Investigational Site, Kalamazoo

60190

Alkermes Investigational Site, Winfield

60611

Alkermes Investigational Site, Chicago

63110

Alkermes Investigational Site, St Louis

63118

Alkermes Investigational Site, St Louis

63128

Alkermes Investigational Site, St Louis

64108

Alkermes Investigational Site, Kansas City

72211

Alkermes Investigational Site, Little Rock

72758

Alkermes Investigational Site, Rogers

75080

Alkermes Investigational Site, Richardson

75115

Alkermes Investigational Site, DeSoto

76104

Alkermes Investigational Site, Fort Worth

77030

Alkermes Investigational Site, Houston

78201

Alkermes Investigational Site, San Antonio

89102

Alkermes Investigational Site, Las Vegas

92013

Alkermes Investigational Site, San Diego

92845

Alkermes Investigational Site, Garden Grove

94305

Alkermes Investigational Site, Stanford

97401

Alkermes Investigational Site, Eugene

Unknown

Alkermes Investigational Site, Vienna

Alkermes Investigational Site, München

Alkermes Investigational Site, Galway

Alkermes Investigational Site, Jerusalem

Alkermes Investigational Site, Tel Litwinsky

Alkermes Investigational Site, Brescia

Alkermes Investigational Site, Naples

Alkermes Investigational Site, Torino

Alkermes Investigational Site, Poznan

Alkermes Investigational Site, Arkhangelsk

Alkermes Investigational Site, Moscow

Alkermes Investigational Site, Roshchino

Alkermes Investigational Site, Rostov-on-Don

Alkermes Investigational Site, Saint Petersburg

Alkermes Investigational Site, Samara

Alkermes Investigational Site, Saratov

Alkermes Investigational Site, Tonnel'nyy

Alkermes Investigational Site, Busan

Alkermes Investigational Site, Daegu

Alkermes Investigational Site, Naju

Alkermes Investigational Site, Seoul

Alkermes Investigational Site, Oviedo

Alkermes Investigational Site, Kharkiv

Alkermes Investigational Site, Kyiv

Alkermes Investigational Site, Lviv

Alkermes Investigational Site, Poltava

Alkermes Investigational Site, Smila

Alkermes Investigational Site, Stepanovka

Alkermes Investigational Site, Guildford

Alkermes Investigational Site, Headington

Alkermes Investigational Site, London

Alkermes Investigational Site, Maidstone

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT03187769 - Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder | Biotech Hunter | Biotech Hunter